MYCN is a well recognized genetic biomarker of high risk and poor outcome in NB and the data in this study further supports this point that the survival rate of the NB patients in the miR-98 low-expression group was significantly higher than that of the miR-98 high-expression group (P < 0.006) (Fig. 1D). The gene discussed is MYCN; the disease is neuroblastoma.